Recombinant Human IL-32θ Induces Polarization Into M1-like Macrophage in Human Monocytic Cells
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
The tumor microenvironment (TME) is formed by several immune cells. Notably, tumor-associated macrophages (TAMs) are existed in the TME that induce angiogenesis, metastasis, and proliferation of cancer cells. Recently, a point-mutated variant of IL-32θ was discovered in breast cancer tissues, which suppressed migration and proliferation through intracellular pathways. Although the relationship between cancer and IL-32 has been previously studied, the effects of IL-32θ on TAMs remain elusive. Recombinant human IL-32θ (rhIL-32θ) was generated using an Escherichia coli expression system. To induce M0 macrophage polarization, THP-1 cells were stimulated with PMA. After PMA treatment, the cells were cultured with IL-4 and IL-13, or rhIL-32θ. The mRNA level of M1 macrophage markers (IL-1β, TNFα, inducible nitric oxide synthase) were increased by rhIL-32θ in M0 macrophages. On the other hand, the M2 macrophage markers (CCL17, CCL22, TGFβ, CD206) were decreased by rhIL-32θ in M2 macrophages. rhIL-32θ induced nuclear translocation of the NF-κB via regulation of the MAPK (p38) pathway. In conclusion, point-mutated rhIL-32θ induced the polarization to M1-like macrophages through the MAPK (p38) and NF-κB (p65/p50) pathways.
Abstract
The tumor microenvironment (TME) is formed by several immune cells. Notably, tumor-associated macrophages (TAMs) are existed in the TME that induce angiogenesis, metastasis, and proliferation of cancer cells. Recently, a point-mutated variant of IL-32θ was discovered in breast cancer tissues, which suppressed migration and proliferation through intracellular pathways. Although the relationship between cancer and IL-32 has been previously studied, the effects of IL-32θ on TAMs remain elusive. Recombinant human IL-32θ (rhIL-32θ) was generated using an Escherichia coli expression system. To induce M0 macrophage polarization, THP-1 cells were stimulated with PMA. After PMA treatment, the cells were cultured with IL-4 and IL-13, or rhIL-32θ. The mRNA level of M1 macrophage markers (IL-1β, TNFα, inducible nitric oxide synthase) were increased by rhIL-32θ in M0 macrophages. On the other hand, the M2 macrophage markers (CCL17, CCL22, TGFβ, CD206) were decreased by rhIL-32θ in M2 macrophages. rhIL-32θ induced nuclear translocation of the NF-κB via regulation of the MAPK (p38) pathway. In conclusion, point-mutated rhIL-32θ induced the polarization to M1-like macrophages through the MAPK (p38) and NF-κB (p65/p50) pathways.
참고문헌 (44)
- Bray F, "The ever-increasing importance of cancer as a leading cause of premature death worldwide", Cancer, 127, pp.3029~3030 (2021)
- Siegel RL, "Cancer statistics, 2023", CA Cancer J Clin, 73, pp.17~48 (2023)
- Xiao Y, "Tumor microenvironment as a therapeutic target in cancer", Pharmacol Ther, 221, pp.107753~ (2021)
- Chen Y, "Tumor-associated macrophages : an accomplice in solid tumor progression", J Biomed Sci, 26, pp.78~ (2019)
- Liu C, "Treg cells promote the SREBP1-dependent metabolic fitness of tumor-promoting macrophages via repression of CD8+ T cell-derived interferon-γ", Immunity, 51, pp.381~397 (2019)
- Denning TL, "Lamina propria macrophages and dendritic cells differentially induce regulatory and interleukin 17-producing T cell responses", Nat Immunol, 8, pp.1086~1094 (2007)
- Strachan DC, "CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8+ T cells", OncoImmunology, 2, pp.e26968~ (2013)
- Kim SH, "Interleukin-32 : a cytokine and inducer of TNFα", Immunity, 22, pp.131~142 (2005)
- Goda C, "Involvement of IL-32 in activation-induced cell death in T cells", Int Immunol, 18, pp.233~240 (2006)
- Kang JW, "Interaction network mapping among IL-32 isoforms", Biochimie, 101, pp.248~251 (2014)
- Aass KR, "Molecular interactions and functions of IL-32", J Leukoc Biol, 109, pp.143~159 (2021)
- Sohn DH, "Structural characteristics of seven IL-32 variants", Immune Netw, 19, pp.e8~ (2019)
- Hong JT, "Interleukin 32, inflammation and cancer", Pharmacol Ther, 174, pp.127~137 (2017)
- Pham TH, "Interleukin-32θ inhibits tumor-promoting effects of macrophage-secreted CCL18 in breast cancer", Cell Commun Signal, 17, pp.53~ (2019)
- Bak Y, "IL-32θ downregulates CCL5 expression through its interaction with PKCδ and STAT3", Cell Signal, 26, pp.3007~3015 (2014)
- Kim MS, "IL-32θ negatively regulates IL-1β production through its interaction with PKCδ and the inhibition of PU. 1 phosphorylation", FEBS Lett, 588, pp.2822~2829 (2014)
- Bak Y, "IL-32θ inhibits stemness and epithelial-mesenchymal transition of cancer stem cells via the STAT3 pathway in colon cancer", Oncotarget, 7, pp.7307~7317 (2016)
- Park HM, "Modulatory effects of point-mutated IL-32θ(A94V)on tumor progression in triple-negative breast cancer cells", Biofactors, 50, pp.294~310 (2024)
- Park JY, "Human IL-32θA94V mutant attenuates monocyte-endothelial adhesion by suppressing the expression of ICAM-1 and VCAM-1 via binding to cell surface receptor integrin αVβ3 and αVβ6 in TNF-α-stimulated HUVECs", Front Immunol, 14, pp.1160301~ (2023)
- Kim KH, "Interleukin-32 monoclonal antibodies for immunohistochemistry, western blotting, and ELISA", J Immunol Methods, 333, pp.38~50 (2008)
- Rhee I, "Diverse macrophages polarization in tumor microenvironment", Arch Pharm Res, 39, pp.1588~1596 (2016)
- Shettigar A, "Targeting molecular cross-talk between tumor cells and tumor associated macrophage as therapeutic strategy in triple negative breast cancer", Int Immunopharmacol, 119, pp.110250~ (2023)
- Pan Y, "Tumor-associated macrophages in tumor immunity", Front Immunol, 11, pp.583084~ (2020)
- Shapouri-Moghaddam A, "Macrophage plasticity, polarization, and function in health and disease", J Cell Physiol, 233, pp.6425~6440 (2018)
- Atri C, "Role of human macrophage polarization in inflammation during infectious diseases", Int J Mol Sci, 19, pp.1801~ (2018)
- Pantschenko AG, "The interleukin-1 family of cytokines and receptors in human breast cancer : implications for tumor progression", Int J Oncol, 23, pp.269~284 (2003)
- Zelová H, "TNF-α signalling and inflammation : interactions between old acquaintances", Inflamm Res, 62, pp.641~651 (2013)
- Yao Y, "Macrophage polarization in physiological and pathological pregnancy", Front Immunol, 10, pp.792~ (2019)
- Heinrich F, "Morphologic, phenotypic, and transcriptomic characterization of classically and alternatively activated canine blood-derived macrophages in vitro", PLoS One, 12, pp.e0183572~ (2017)
- Qin S, "Sulforaphane attenuates microglia-mediated neuronal necroptosis through down-regulation of MAPK", NF-κB signaling pathways in LPS-activated BV-2 microglia, 2018, pp.133, 218~235
- Koh YC, "Chemopreventive effects of phytochemicals and medicines on M1", M2 polarized macrophage role in inflammation-related diseases, 2018, pp.19, 2208~
- Margraf A, "Immune cell plasticity in inflammation : insights into description and regulation of immune cell phenotypes", Cells, 11, pp.1824~ (2022)
- Khan SU, "Reprogramming tumor-associated macrophages as a unique approach to target tumor immunotherapy", Front Immunol, 14, pp.1166487~ (2023)
- Boutilier AJ, "Macrophage polarization states in the tumor microenvironment", Int J Mol Sci, 22, pp.6995~ (2021)
- Yunna C, "Macrophage M1", M2 polarization, 2020, pp.877, 173090~
- Gensel JC, "Macrophage activation and its role in repair and pathology after spinal cord injury", Brain Res, 1619, pp.1~11 (2015)
- Najafi M, "Macrophage polarity in cancer : a review", J Cell Biochem, 120, pp.2756~2765 (2019)
- Wang H, "The impact of the tumor microenvironment on macrophage polarization in cancer metastatic progression", Int J Mol Sci, 22, pp.6560~ (2021)
- Amer HT, "The monocyte, a maestro in the tumor microenvironment(TME)of breast cancer", Cancers(Basel), 14, pp.5460~ (2022)
- Liu J, "New insights into M1", M2 macrophages : key modulators in cancer progression, 2021, pp.21, 389~
- Mantovani A, "Tumour-associated macrophages as treatment targets in oncology", Nat Rev Clin Oncol, 14, pp.399~416 (2017)
- Debela DT, "New approaches and procedures for cancer treatment : current perspectives", SAGE Open Med, 9, pp.20503121211034366~ (2021)
- Shin MH, "Recent advances in car-based solid tumor immunotherapy", Cells, 12, pp.1606~ (2023)
- Sterner RC, "CAR-T cell therapy : current limitations and potential strategies", Blood Cancer J, 11, pp.69~ (2021)